A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques

Clinical and Vaccine Immunology

Volumn 19, Issue 11, 2012, Pages 1730-1745

  Quinn, Conrad P ^a   Sabourin, Carol L ^b   Niemuth, Nancy A ^b   Li, Han ^a   Semenova, Vera A ^a   Rudge, Thomas L ^b   Mayfield, Heather J ^b   Schiffer, Jarad ^a   Mittler, Robert S ^c   Ibegbu, Chris C ^c   Wrammert, Jens ^c   Ahmed, Rafi ^c   Brys, April M ^b   Hunt, Robert E ^b   Levesque, Denyse ^c   Estep, James E ^b   Barnewall, Roy E ^b   Robinson, David M ^b   Plikaytis, Brian D ^a   Marano, Nina ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACTERIAL ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; PROTECTIVE ANTIGEN; PROTECTIVE ANTIGEN ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTHRAX; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; HUMORAL IMMUNITY; MEMORY CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RHESUS MONKEY; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

ANIMALS; ANTHRAX; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, BACTERIAL; ANTITOXINS; B-LYMPHOCYTES; BACTERIAL TOXINS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN G; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; INTERLEUKIN-4; MACACA MULATTA; RESPIRATORY TRACT INFECTIONS; T-LYMPHOCYTES; TIME FACTORS; VACCINATION;

EID: 84868232784     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00324-12     Document Type: Article

References (60)

1. Abboud N, et al. 2009. Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies. J. Biol. Chem. 284:25077-25086.
2. Beedham RJ, Turnbull PC, Williamson ED. 2001. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19:4409-4416. (Pubitemid 32718664)
3. Bouzianas DG. 2010. Current and future medical approaches to combat the anthrax threat. J. Med. Chem. 53:4305-4331.
4. Boyer AE, et al. 2009. Kinetics of lethal factor and poly-D-glutamic acid antigenemia during inhalation anthrax in rhesus macaques. Infect. Immun. 77:3432-3441.
5. Chen Z, et al. 2006. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J. Infect. Dis. 193: 625-633. (Pubitemid 43271496)
6. Cirino NM, et al. 1999. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect. Immun. 67:2957-2963. (Pubitemid 29244714)
7. Crotty S, Aubert RD, Glidewell J, Ahmed R. 2004. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J. Immunol. Methods 286:111-122. (Pubitemid 38490401)
8. Crotty S, et al. 2003. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J. Immunol. 171:4969-4973. (Pubitemid 37432774)
9. Fellows PF, et al. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247. (Pubitemid 32324053)
10. Fritz DL, et al. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab. Invest. 73:691-702.
11. Gubbins MJ, et al. 2006. Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen. FEMS Immunol. Med. Microbiol. 47:436-443. (Pubitemid 44035895)
12. Hanson JF, Taft SC, Weiss AA. 2006. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin. Vaccine Immunol. 13:208-213. (Pubitemid 43383788)
13. Hewetson JF, et al. 2008. An in vivo passive protection assay for the evaluation of immunity in AVA-vaccinated individuals. Vaccine 26:4262-4266.
14. Hornung RW, Reed L. 1990. Estimation of average concentration in the presence of nondetectable values. Appl. Occup. Environ. Hyg. 5:46-51. (Pubitemid 20094575)
15. Joellenbeck LM, et al. 2003. An assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program. Institute of Medicine, National Academies Press, Washington, DC.
16. Kelly-Cirino CD, Mantis NJ. 2009. Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen. Infect. Immun. 77:4859-4867.
17. Kobiler D, et al. 2002. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Immun. 70:544-560.
18. Kwok WW, et al. 2008. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-specific CD4+ T cells with a phenotype distinct from that of naïve PA T cells. Infect. Immun. 76:4538-4545.
19. Laughlin EM, et al. 2007. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine. Infect. Immun. 75:1852-1860. (Pubitemid 46559454)
20. Li H, et al. 2008. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J. Immunol. Methods 333:89-106.
21. Little SF, Ivins BE, Fellows PF, Friedlander AM. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175. (Pubitemid 27513566)
22. Little SF, et al. 2006. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine. Vaccine 24:2530-2536. (Pubitemid 43290383)
23. Little SF, Lowe JR. 1991. Location of receptor-binding region of protective antigen from Bacillus anthracis. Biochem. Biophys. Res. Commun. 180:531-537.
24. Little SF, et al. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142:707-715. (Pubitemid 26093657)
25. Little SF, et al. 2004. Development of an in vitro-based potency assay for anthrax vaccine. Vaccine 22:2843-2852. (Pubitemid 38900663)
26. Little SF, Webster WM, Norris SL, Andrews GP. 2004. Evaluation of an anti-rPA IgG ELISA for measuring the antibody response in mice. Biologicals 32:62-69. (Pubitemid 39348754)
27. Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. 2010. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 28:1056-1061.
28. Longworth E, et al. 2002. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 20:2592-2596. (Pubitemid 34615600)
29. Mabry R, et al. 2005. Passive protection against anthrax by using a highaffinity antitoxin antibody fragment lacking an Fc region. Infect. Immun. 73:8362-8368. (Pubitemid 41740327)
30. Marano N, et al. 2008. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 300:1532-1543.
31. McBride BW, et al. 1998. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16:810-817. (Pubitemid 28236650)
32. Pahar B, Li J, Rourke T, Miller CJ, McChesney MB. 2003. Detection of antigen-specific T cell interferon gamma expression by ELISPOT and cytokine flow cytometry assays in rhesus macaques. J. Immunol. Methods 282:103-115. (Pubitemid 37357037)
33. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. 1998. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc. Natl. Acad. Sci. U. S. A. 95:3071-3076. (Pubitemid 28135856)
34. Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. 2004. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol. Mol. Biol. Rev. 68:617-629. (Pubitemid 39628529)
35. Pitt ML, et al. 1999. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 87:304.
36. Pitt ML, et al. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773. (Pubitemid 32800762)
37. Pittman PR, Gibbs PH, Cannon TL, Friedlander AM. 2001. Anthrax vaccine: short-term safety experience in humans. Vaccine 20:972-978. (Pubitemid 34015841)
38. Radjainia M, Hyun JK, Leysath CE, Leppla SH, Mitra AK. 2010. Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex. Proc. Natl. Acad. Sci. U. S. A. 107:14070-14074.
39. Reason D, Liberato JJ, Sun Keitel W, Zhou J. 2009. Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infect. Immun. 77:2030-2035.
40. Reuveny S, et al. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893. (Pubitemid 32332179)
41. Rosenfeld R, et al. 2009. Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infection. PLoS One 4:e6351. doi:10.1371/journal.pone.0006351.
42. Sawada-Hirai R, et al. 2004. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J. Immune Based Ther. Vaccines 2:5-20.
43. Scinicariello F, Engleman CN, Jayashankar L, McClure HM, Attanasio R. 2004. Rhesus macaque antibody molecules: sequences and heterogeneity of alpha and gamma constant regions. Immunology 111:66-74. (Pubitemid 38091051)
44. Semenova VA, et al. 2004. Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin. Diagn. Lab. Immunol. 11:919-923. (Pubitemid 39280599)
45. Shearer MH, Dark RD, Chodosh J, Kennedy RC. 1999. Comparison and characterization of immunoglobulin G subclasses among primate species. Clin. Diagn. Lab. Immunol. 6:953-958. (Pubitemid 29529994)
46. Singh Y, Klimpel KR, Quinn CP, Chaudhary VK, Leppla SH. 1991. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J. Biol. Chem. 266:15493-15497. (Pubitemid 21907675)
47. Staats HF, et al. 2007. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity. Infect. Immun. 75:5443-5452. (Pubitemid 350033633)
48. Stratton KR, Durch JS, Lawrence RS (ed). 2001. Vaccines for the 21st century: a tool for decision making. Institute of Medicine, National Academy Press, Washington, DC.
49. Taft SC, Weiss AA. 2008. Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor. Clin. Vaccine Immunol. 15:71-75. (Pubitemid 351966536)
50. Turnbull PC, Broster MG, Carman JA, Manchee RJ, Melling J. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52:356-363. (Pubitemid 16117786)
51. Turnbull PC, et al. 2004. Vaccine-induced protection against anthrax in cheetah (Acinonyx jubatus) and black rhinoceros (Diceros bicornis). Vaccine 22:3340-3347. (Pubitemid 39078751)
52. Twenhafel NA, Leffel E, Pitt ML. 2007. Pathology of inhalational anthrax infection in the African green monkey. Vet. Pathol. 44:716-721. (Pubitemid 47451244)
53. Varughese M, Teixeira AV, Liu S, Leppla SH. 1999. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect. Immun. 67:1860-1865. (Pubitemid 29144407)
54. Vasconcelos D, et al. 2003. Pathology of inhalation anthrax in cynomolgus monkeys (Macaca fascicularis). Lab. Invest. 83:1201-1209. (Pubitemid 37013055)
55. Welkos S, Friedlander A, Weeks S, Little S, Mendelson I. 2002. In-vitro characterisation of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J. Med. Microbiol. 51:821-831. (Pubitemid 35222782)
56. Welkos S, Little S, Friedlander A, Fritz D, Fellows P. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147: 1677-1685. (Pubitemid 32544833)
57. Williamson ED, et al. 2005. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect. Immun. 73:5978-5987. (Pubitemid 41193036)
58. Wright JG, Quinn CP, Shadomy S, Messonnier N. 2010. Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Morb. Mortal. Wkly. Rep. 59:1-30.
59. Zaucha GM, Pitt LM, Estep J, Ivins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982-992. (Pubitemid 28521045)
60. Zhao P, Liang X, Kalbfleisch J, Koo HM, Cao B. 2003. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum. Antibodies 12:129-135. (Pubitemid 38657149)